MX2022011847A - Proteínas de unión multiespecíficas y métodos para desarrollarlas. - Google Patents

Proteínas de unión multiespecíficas y métodos para desarrollarlas.

Info

Publication number
MX2022011847A
MX2022011847A MX2022011847A MX2022011847A MX2022011847A MX 2022011847 A MX2022011847 A MX 2022011847A MX 2022011847 A MX2022011847 A MX 2022011847A MX 2022011847 A MX2022011847 A MX 2022011847A MX 2022011847 A MX2022011847 A MX 2022011847A
Authority
MX
Mexico
Prior art keywords
binding proteins
methods
multispecific binding
developing
same
Prior art date
Application number
MX2022011847A
Other languages
English (en)
Inventor
Qing Chai
Xiufeng Wu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2022011847A publication Critical patent/MX2022011847A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Proteínas de unión multiespecíficas que se unen a un primer antígeno y a un segundo antígeno y métodos de purificación de proteínas de unión multiespecíficas.
MX2022011847A 2020-03-25 2021-03-18 Proteínas de unión multiespecíficas y métodos para desarrollarlas. MX2022011847A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994509P 2020-03-25 2020-03-25
PCT/US2021/022935 WO2021194839A1 (en) 2020-03-25 2021-03-18 Multispecific binding proteins and methods of developing the same

Publications (1)

Publication Number Publication Date
MX2022011847A true MX2022011847A (es) 2023-01-04

Family

ID=75478220

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011847A MX2022011847A (es) 2020-03-25 2021-03-18 Proteínas de unión multiespecíficas y métodos para desarrollarlas.

Country Status (11)

Country Link
US (1) US20230242671A1 (es)
EP (1) EP4126929A1 (es)
JP (1) JP2023525444A (es)
KR (1) KR20220156912A (es)
CN (1) CN115605506A (es)
AU (1) AU2021241426A1 (es)
BR (1) BR112022018452A2 (es)
CA (1) CA3173162A1 (es)
IL (1) IL296428A (es)
MX (1) MX2022011847A (es)
WO (1) WO2021194839A1 (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1948691A1 (en) * 2005-11-17 2008-07-30 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN
ES2395969T3 (es) 2006-03-24 2013-02-18 Merck Patent Gmbh Dominios de proteínas heterodiméricas genéticamente modificados
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
EP2975051B1 (en) 2009-06-26 2021-04-14 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
PT2768857T (pt) 2011-10-19 2020-01-27 Novimmune Sa Métodos para purificar anticorpos
ES2728301T3 (es) 2012-03-13 2019-10-23 Novimmune Sa Anticuerpos biespecíficos fácilmente aislados con formato de inmunoglobulina nativa
WO2014150973A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
PE20190340A1 (es) * 2016-06-10 2019-03-07 Eisai Randd Man Co Ltd Inmunglobulinas conjugadas con lisina
BR112019025612A2 (pt) * 2017-06-05 2020-06-16 Janssen Biotech, Inc. Métodos de manipular carga de superfície para a produção de anticorpos biespecíficos

Also Published As

Publication number Publication date
CN115605506A (zh) 2023-01-13
KR20220156912A (ko) 2022-11-28
BR112022018452A2 (pt) 2022-11-01
IL296428A (en) 2022-11-01
WO2021194839A1 (en) 2021-09-30
JP2023525444A (ja) 2023-06-16
AU2021241426A1 (en) 2022-10-06
US20230242671A1 (en) 2023-08-03
CA3173162A1 (en) 2021-09-30
EP4126929A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
MX2019000730A (es) Proteinas multiespecificas de union al antigeno y metodos de uso de estas.
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
MY199406A (en) Bispecific antibodies specifically binding to pd1 and lag3
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2020009116A (es) Proteinas triespecificas de union a antigenos.
EP3928790A4 (en) CD3 ANTIGEN-BINDING FRAGMENT AND APPLICATION THEREOF
MX2021008216A (es) Anticuerpos anti-tigit.
AU2017255888A1 (en) Humanized anti-BASIGIN antibodies and the use thereof
CO2021000497A2 (es) Proteína de unión al antígeno anti-steap1
MX2022007962A (es) Anticuerpo anti-lilrb1 y usos del mismo.
MX2022013310A (es) Anticuerpos especificos para kras y sus usos.
EP3902840A4 (en) MULTISPECIFIC ANTIGEN-BINDING PROTEINS CAPABLE OF BINDING CD19 AND CD3, AND THEIR USE
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
MX2022011847A (es) Proteínas de unión multiespecíficas y métodos para desarrollarlas.
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
BR112022008652A2 (pt) Anticorpos biespecíficos hla-a2/wt1 x cd3, uso de um anticorpo biespecífico, método para tratar câncer em um indivíduo, kit e invenção
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
MX2021001604A (es) Tratamiento del cáncer con un anticuerpo.
WO2018232278A3 (en) PHOSPHO-RAB ANTIBODIES, ASSAYS AND METHODS OF USE
AR116101A1 (es) Proteína de unión al antígeno anti-steap1
MX2021012652A (es) Metodos para el tratamiento de sujetos con artritis psoriasica.